Inotiv, Inc. (NOTV)

In the past six months, Inotiv's stock has experienced significant fluctuations. As of February 5, 2026, the closing stock price was $0.39, and the market capitalization as of January 30, 2026, was $17.20 million. Key events include the Q4 2025 earnings report, participation in investor conferences, filing a $350 million mixed securities shelf, scheduling the Q1 2026 financial results report, and partnerships with LifeNet Health and VUGENE.

Fiscal Q1 is typically a seasonally slower quarter for Inotiv. The company's Q1 fiscal 2024 performance showed some resilience, with steady growth in the DSA business and a healthy backlog. Revenue for small research models has seen a decrease due to lower demand, while pricing in the NHP business has contributed to increased revenue and margins in the Research Models and Services segment.

Inotiv, Inc. is a contract research organization providing nonclinical and analytical drug discovery and development services, along with research models and related products. The company operates in two segments: Discovery and Safety Assessment (DSA), which offers nonclinical research services, and Research Models and Services (RMS), which focuses on the commercial production and sale of research models, diets, bedding, and bioproducts.

Inotiv, Inc. is headquartered in West Lafayette, Indiana, and has a global presence. The company operates in the United States, the Netherlands, other parts of North America, Europe, the Pacific Rim, and internationally, serving over 250 pharmaceutical and biotechnology clients.

In the past year, Inotiv's brand reputation has been positively influenced by strategic partnerships and industry recognition. The company was ranked 182nd Fastest-Growing Company in North America on the 2025 Deloitte Technology Fast 500™. Recent collaborations demonstrate a commitment to innovation and advancing scientific capabilities.

Inotiv, Inc. has 83 institutional owners and shareholders holding a total of 8,330,916 shares, including major holders like Vanguard Group Inc. and Balyasny Asset Management Llc. Individual insider owners include P2 Capital Partners LLC, John E. Sagartz, Andrew H. Baker, Robert Leasure Jr. (CEO), Kimberly L. Sagartz, Scott Cragg, and Peter Kissinger. Insiders have shown net selling activity over the last 12 and 3 months.